Membrane estrogen receptor-α levels in MCF-7 breast cancer cells predict cAMP and proliferation responses

Breast Cancer Research

Cheryl S Watson¹  Bahiru Gametchu²  Dragoslava Zivadinovic¹ 

[1] Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas, USA;Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

关键词: protein kinase A;    dose response;    17β-estradiol;    adenylyl cyclase;   

Others  :  1115056
DOI  :  10.1186/bcr958

 received in 2004-04-16, accepted in 2004-10-07,  发布年份 2004

【 摘 要 】

Introduction

17β-estradiol (E₂) can rapidly induce cAMP production, but the conditions under which these cAMP levels are best measured and the signaling pathways responsible for the consequent proliferative effects on breast cancer cells are not fully understood. To help resolve these issues, we compared cAMP mechanistic responses in MCF-7 cell lines selected for low (mER^low) and high (mER^high) expression of the membrane form of estrogen receptor (mER)-α, and thus addressed the receptor subform involved in cAMP signaling.

Methods

MCF-7 cells were immunopanned and subsequently separated by fluorescence activated cell sorting into mER^high (mER-α-enriched) and mER^low (mER-α-depleted) populations. Unique (compared with previously reported) incubation conditions at 4°C were found to be optimal for demonstrating E₂-induced cAMP production. Time-dependent and dose-dependent effects of E₂ on cAMP production were determined for both cell subpopulations. The effects of forskolin, 8-CPT cAMP, protein kinase A inhibitor (H-89), and adenylyl cyclase inhibitor (SQ 22,536) on E₂-induced cell proliferation were assessed using the crystal violet assay.

Results

We demonstrated a rapid and transient cAMP increase after 1 pmol/l E₂ stimulation in mER^high cells; at 4°C these responses were much more reliable and robust than at 37°C (the condition most often used). The loss of cAMP at 37°C was not due to export. 3-Isobutyl-1-methylxanthine (IBMX; 1 mmol/l) only partially preserved cAMP, suggesting that multiple phosphodiesterases modulate its level. The accumulated cAMP was consistently much higher in mER^high cells than in mER^low cells, implicating mER-α levels in the process. ICI172,780 blocked the E₂-induced response and 17α-estradiol did not elicit the response, also suggesting activity through an estrogen receptor. E₂ dose-dependent cAMP production, although biphasic in both cell types, was responsive to 50-fold higher E₂ concentrations in mER^high cells. Proliferation of mER^low cells was stimulated over the whole range of E₂concentrations, whereas the number of mER^high cells was greatly decreased at concentrations above 1 nmol/l, suggesting that estrogen over-stimulation can lead to cell death, as has previously been reported, and that mER-α participates. E₂-mediated activation of adenylyl cyclase and downstream participation of protein kinase A were shown to be involved in these responses.

Conclusion

Rapid mER-α-mediated nongenomic signaling cascades generate cAMP and downstream signaling events, which contribute to the regulation of breast cancer cell number.

【 授权许可】

   
2004 Zivadinovic et al., licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 6.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Leung PCK, Steele GL: Intracellular signaling in the gonads. Endocrine Reviews 1992, 13:476-498.
• [2]Stumpel F, Scholtka B, Jungermann K: Stimulation by portal insulin of intestinal glucose absorption via hepatoenteral nerves and prostaglandin E2 in the isolated, jointly perfused small intestine and liver of the rat. Ann N Y Acad Sci 2000, 915:111-116.
• [3]Lohmann SM, Fischmeister R, Walter U: Signal transduction by cGMP in heart. Basic Res Cardiol 1991, 86:503-514.
• [4]Albrecht ED, Pepe GJ: Placental steroid hormone biosynthesis in primate pregnancy. Endocr Rev 1990, 11:124-150.
• [5]Wood JR, Strauss JF III: Multiple signal transduction pathways regulate ovarian steroidogenesis. Rev Endocr Metab Disord 2002, 3:33-46.
• [6]Dremier S, Coulonval K, Perpete S, Vandeput F, Fortemaison N, Van Keymeulen A, Deleu S, Ledent C, Clement S, Schurmans S, et al.: The role of cyclic AMP and its effect on protein kinase A in the mitogenic action of thyrotropin on the thyroid cell. Ann N Y Acad Sci 2002, 968:106-121.
• [7]Tierney T, Robinson ICAF: Increased lactotrophs despite decreased somatotrophs in the dwarf (dw/dw) rat: a defect in the regulation of lactotroph/somatotroph cell fate? J Endocrinol 2002, 175:435-446.
• [8]Starzec AB, Spanakis E, Nehme A, Salle V, Veber N, Mainguene C, Planchon P, Valette A, Prevost G, Israel L: Proliferative responses of epithelial-cells to 8-bromo-cyclic AMP and to a phorbol ester change during breast pathogenesis. J Cell Physiol 1994, 161:31-38.
• [9]Cho-Chung YS: Suppression of malignancy targeting cyclic AMP signal transducing proteins. Biochem Soc Trans 1992, 20:425-430.
• [10]Kim SN, Ahn YH, Kim SG, Park SD, Yoon SCC, Hong SH: 8-Cl-cAMP induces cell cycle-specific apoptosis ln human cancer cells. Int J Cancer 2001, 93:33-41.
• [11]Tang WJ, Yan S, Drum CL: Class III adenylyl cyclases: regulation and underlying mechanisms. Adv Second Messenger Phosphoprotein Res 1998, 32:137-151.
• [12]Soderling SH, Beavo JA: Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 2000, 12:174-179.
• [13]Sutter-Dub MT: Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids 2002, 67:77-93.
• [14]Gametchu B: Glucocorticoid receptor-like antigen in lymphoma cell membranes: correlation to cell lysis. Science 1987, 236:456-461.
• [15]Pappas TC, Gametchu B, Watson CS: Membrane estrogen receptor-enriched GH3/B6 cells have an enhanced non-genomic response to estrogen. Endocrine 1995, 3:743-749.
• [16]Gametchu B, Watson C, Shih C, Dashew B: Studies on the arrangement of glucocorticoid receptors in the plasma membrane of S-49 lymphoma cells. Steroids 1991, 56:411-419.
• [17]Campbell CH, Watson CS: A comparison of membrane vs. intracellular estrogen receptor-alpha in GH3/B6 pituitary tumor cells using a quantitative plate immunoassay. Steroids 2001, 66:727-736.
• [18]Campbell CH, Bulayeva N, Brown DB, Gametchu B, Watson CS: Regulation of the membrane estrogen receptor-a: role of cell density, serum, cell passage number, and estradiol. FASEB J 2002, 16:1917-1927.
• [19]Lottering M-L, Haag M, Seegers JC: Effects of 17β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 1992, 52:5926-5932.
• [20]Jensen J, Kitlen JW, Briand P, Labrie F, Lykkesfeldt AE: Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J Steroid Biochem Mol Biol 2003, 84:469-478.
• [21]Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson R, Santner S, Yue W, Shim WS: Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001, 79:115-125.
• [22]Zivadinovic D, Watson CS: Membrane estrogen receptor-a levels predict estrogen-induced ERK1/2 activation in MCF-7 cells. Breast Cancer Res 2004, 7:R130-R144.
• [23]Aronica SM, Kraus WL, Katzenellenbogen BS: Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA 1994, 91:8517-8521.
• [24]Fortunati N, Fissore F, Fazzari A, Piovano F, Catalano MG, Becchis M, Berta L, Frairia R: Estradiol induction of cAMP in breast cancer cells is mediated by foetal calf serum (FCS) and sex hormone-binding globulin (SHBG). J Steroid Biochem Mol Biol 1999, 70:73-80.
• [25]Kiefer T, Ram PT, Yuan L, Hill SM: Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 2002, 71:37-45.
• [26]Boldyreff B, Wehling M: Rapid aldosterone actions: from the membrane to signaling cascades to gene transcription and physiological effects. J Steroid Biochem Mol Biol 2003, 85:375-381.
• [27]Watson CS, Gametchu B: Membrane-initiated steroid actions and the proteins which mediate them [review]. Proc Soc Exp Biol Med 1999, 220:9-19.
• [28]Cato AC, Nestl A, Mink S: Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE 2002, 2002:RE9.
• [29]Chin KV, Yang WL, Ravatn R, Kita T, Reitman E, Vettori D, Cvijic ME, Shin M, Iacono L: Reinventing the wheel of cyclic AMP: novel mechanisms of cAMP signaling. Ann N Y Acad Sci 2002, 968:49-64.
• [30]Ropero AB, Soria B, Nadal A: A nonclassical estrogen membrane receptor triggers rapid differential actions in the endocrine pancreas. Mol Endocrinol 2002, 16:497-505.
• [31]Pappas TC, Gametchu B, Watson CS: Membrane estrogen receptors identified by multiple antibody and impeded ligand labeling. FASEB J 1995, 9:404-410.
• [32]Norfleet AM, Clarke C, Gametchu B, Watson CS: Antibodies to the estrogen receptor-a modulate prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors. FASEB J 2000, 14:157-165.
• [33]Watson CS, Norfleet AM, Pappas TC, Gametchu B: Rapid actions of estrogens in GH3/B6 pituitiary tumor cells via a plasma membrane version of estrogen receptor-alpha. Steroids 1999, 64:5-13.
• [34]Jansson SE, Gripenberg J, Karonen SL, Wasenius VM, Pantzar P, Kontula K, Karkkainen J, Adlercreutz H: Cytochemical demonstration of estrogen binding-sites in breast-cancer by estradiol covalently linked to horseradish-peroxidase. Eur J Cancer Clin Oncol 1985, 21:625-630.
• [35]Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR: Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci USA 2000, 97:5930-5935.
• [36]Binder M: Oestradiol-BSA conjugates for receptor histochemistry: problems of stability and interactions with cytosol. Histochem J 1984, 16:1003-1023.
• [37]Lippert C, Seeger H, Mueck AO: The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci 2003, 72:877-883.
• [38]Scott CD, Baxter RC: Insulin-like growth factor-II receptors in cultured rat hepatocytes: regulation by cell density. J Cell Physiol 1987, 133:532-538.
• [39]Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol. J Natl Cancer Inst 2001, 93:1714-1723.
• [40]Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S, Santen RJ: Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998, 139:4164-4174.
• [41]Kushner PJ, Hort E, Shine J, Baxter JD, Greene GL: Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens. Mol Endocrinol 1990, 4:1465-1473.
• [42]Razandi M, Pedram A, Levin ER: Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol 2000, 14:1434-1447.
• [43]Lowe WL Jr, Fu R, Banko M: Growth factor-induced transcription via the serum response element is inhibited by cyclic adenosine 3',5'-monophosphate in MCF-7 breast cancer cells. Endocrinology 1997, 138:2219-2226.
• [44]Houslay MD, Kolch W: Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol 2000, 58:659-668.
• [45]Chen J, Bander JA, Santore TA, Chen Y, Ram PT, Smit MJ, Iyengar R: Expression of Q227L-galphas in MCF-7 human breast cancer cells inhibits tumorigenesis. Proc Natl Acad Sci USA 1998, 95:2648-2652.
• [46]Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M, Di Marzo V: Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 1999, 463:235-240.
• [47]Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Bottero D, Varricchio L, Nanayakkara M, Rotondi A, et al.: Sex steroid hormones act as growth factors. J Steroid Biochem Mol Biol 2002, 83:31-35.
• [48]Filardo EJ, Quinn JA, Frackelton AR, Bland KI: Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002, 16:70-84.
• [49]Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA: Androgen and estrogen signaling at the cell membrane via G-proteins and cyclic adenosine monophosphate. Steroids 1999, 64:100-106.
• [50]Keshamouni VG, Mattingly RR, Reddy KB: Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. J Biol Chem 2002, 277:22558-22565.